Sorafenib and thyroid cancer
P Fallahi, SM Ferrari, F Santini, A Corrado, G Materazzi… - BioDrugs, 2013 - Springer
Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-
proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of …
proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of …
Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum
A Thorwarth, S Schnittert-Hübener… - Journal of medical …, 2014 - jmg.bmj.com
Background NKX2-1 encodes a transcription factor with large impact on the development of
brain, lung and thyroid. Germline mutations of NKX2-1 can lead to dysfunction and …
brain, lung and thyroid. Germline mutations of NKX2-1 can lead to dysfunction and …
[HTML][HTML] TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors
M Matsuse, T Yabuta, V Saenko, M Hirokawa… - Scientific reports, 2017 - nature.com
Although most papillary thyroid carcinomas (PTCs) have a good prognosis, a small but
certain fraction shows aggressive behavior. Therefore, a novel and well-performing …
certain fraction shows aggressive behavior. Therefore, a novel and well-performing …
Light-controlled inhibition of BRAFV600E kinase
MWH Hoorens, ME Ourailidou, T Rodat… - European Journal of …, 2019 - Elsevier
Metastatic melanoma is amongst the most difficult types of cancer to treat, with current
therapies mainly relying on the inhibition of the BRAF V600E mutant kinase. However …
therapies mainly relying on the inhibition of the BRAF V600E mutant kinase. However …
Aggressive thyroid cancer: targeted therapy with sorafenib
A Corrado, SM Ferrari, U Politti, V Mazzi… - Minerva …, 2017 - arpi.unipi.it
Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both anti
proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of …
proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of …
[HTML][HTML] Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients
The most common BRAF mutation in thyroid cancer is c. 1799T> A (p. Val600Glu), and other
BRAF mutations are rarely reported. We investigated the clinicopathological features of …
BRAF mutations are rarely reported. We investigated the clinicopathological features of …
SNAIL induces epithelial-to-mesenchymal transition and cancer stem cell–like properties in aldehyde dehydroghenase–negative thyroid cancer cells
K Yasui, M Shimamura, N Mitsutake, Y Nagayama - Thyroid, 2013 - liebertpub.com
Background: Epithelial-to-mesenchymal transition (EMT) is thought to play a critical role in
the invasion and metastasis of cancer and to be associated with cancer stem cell (CSC) …
the invasion and metastasis of cancer and to be associated with cancer stem cell (CSC) …
[HTML][HTML] Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
Background BRAF is the most frequently mutated gene in differentiated thyroid cancer
(DTC). Previous studies on DTC have well documented high rates of the BRAF V600E …
(DTC). Previous studies on DTC have well documented high rates of the BRAF V600E …
Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights
BACKGROUND Mutational analysis is reshaping the practice of fine‐needle aspiration
cytology for the diagnosis of thyroid nodules. The v‐Raf murine sarcoma viral oncogene …
cytology for the diagnosis of thyroid nodules. The v‐Raf murine sarcoma viral oncogene …
Characterization of BRAFThr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling
H Watanabe, Y Inoue, M Karayama, S Yazawa… - JCO Precision …, 2024 - ascopubs.org
PURPOSE Understanding the function of BRAF mutants is crucial for determining the best
treatment strategy. This study aimed to characterize a rare BRAF variant, BRAF Thr599dup …
treatment strategy. This study aimed to characterize a rare BRAF variant, BRAF Thr599dup …